Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2019

View Archived Issues

LncRNA NEAT1 signaling drives aggressive endometrial cancer progression

Second-generation imipridone ONC-212 demonstrates improved antitumor activity in AML models

Ascletis receives IND approval for ASC-18 in China

Evotec and Lygature announce new GNA NOW project against antimicrobial resistance

Asahi Kasei Pharma presents future plan for phase III study of ART-123

Dosing starts in phase I study of DNL-758

Positive results from phase II study of SQX-770 in the prevention of herpes labialis

Idorsia Pharmaceuticals discovers IDO-1 and/or TDO inhibitors

Influenza cap-dependent endonuclease inhibitors described by Ginkgo Pharmaceutical

Vertex Pharmaceuticals patents DNA-dependent protein kinase inhibitors

Nanjing TransThera Biosciences discloses TRYO3/ AXL/MERTK/CSF-1R inhibitors

Adenosine A2A receptor antagonists disclosed by Sichuan Kelun-Biotech Biopharmaceutical

Researchers report findings on distribution studies of ENV-101

Derivatives of Nectandra leucantha neolignans with activity against Trypanosoma cruzi

Small molecule WX2-43 targets PRMT5-KLF4 for triple-negative breast cancer treatment

Eloxx Pharmaceuticals initiates phase II study for ELX-02 in cystinosis

Pivotal IMPALA study of lefitolimod in colorectal cancer misses primary endpoint

Sanofi reports updates for Dupixent as treatment in adolescents and children with atopic dermatitis

Basilea announces positive results from phase III TARGET study of ceftobiprole in ABSSSI

IPH-4102 shows promising activity in cutaneous T-cell lymphoma in first-in-human study

Mitsubishi Tanabe Pharma announces initiation of development of gene therapy for hemophilia B

Zydus completes phase III trials of saroglitazar in type 2 diabetes mellitus

HIV: exosomes potentiate inflammation in bystander cells

FDA clears IND application for phase IIb ASTONISH study of nangibotide

Complete wound healing reported in first patient treated in phase II study of RGN-137

Galectin Therapeutics submits phase III protocol for NASH-RX trial to the FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...